Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress
Key Highlights
- ➤Neurocrine will present its scientific journey and neuropsychiatry pipeline at NEI November 5-8.
- ➤Posters cover major depressive disorder, schizophrenia, and tardive dyskinesia research.
- ➤KINECT-PRO analyses assess valbenazine’s quality-of-life and functioning effects in tardive dyskinesia.
- ➤INGREZZA is FDA-approved for tardive dyskinesia and Huntington’s disease chorea.
Expert Statements
Dimitri E. Grigoriadis, Distinguished Scholar, Neurocrine Biosciences
“We're proud to share more of Neurocrine's scientific journey with the neuroscience community at NEI, including the challenges and lessons that have shaped our approach over more than three decades and the work underway today across psychiatry. Our progress has always been grounded in following the science, learning along the way, and staying focused on the needs of patients. We look forward to sharing new insights across major depressive disorder, schizophrenia and tardive dyskinesia, and to continuing to build on that foundation as we pursue new medicines for people living with serious neuropsychiatric conditions.”
Neurocrine Biosciences to Spotlight Its Scientific Journey and Growing Neuropsychiatry Pipeline at 2026 NEI Fall Congress PR Newswire
SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its participation in the 2026 Neuroscience Education Institute (NEI) Fall Congress, taking place Nov. 5-8 in Colorado Springs, Colo. Through a special industry-sponsored session, "Inspired by Patients, Driven by Science: The Neurocrine Story," Neurocrine will take attendees behind the science, challenges, and breakthroughs that have shaped the company over more than three decades and explore how those experiences are informing its vision for the future of neuroscience and the treatment of neuropsychiatric conditions. Additionally, the company will share poster presentations highlighting the breadth of its expanding work in neuropsychiatry, including major depressive disorder and schizophrenia, alongside continued research in tardive dyskinesia.
Get started
Create a free account to read the full story.